Edition:
United States

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

6.95USD
23 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.95
Open
$7.00
Day's High
$7.10
Day's Low
$6.85
Volume
78,337
Avg. Vol
138,254
52-wk High
$14.00
52-wk Low
$5.85

Chart for

About

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes... (more)

Overall

Beta: --
Market Cap(Mil.): $563.00
Shares Outstanding(Mil.): 81.01
Dividend: --
Yield (%): --

Financials

  ADRO.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.21 -- --
ROI: -21.80 -0.74 13.19
ROE: -38.07 -2.80 15.00

BRIEF-Aduro Announces Milestone Achieved Under Merck Collaboration

* ADURO ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF ANTI-CD27 PHASE I TRIAL IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage:

Mar 05 2018

BRIEF-Aduro Biotech Promotes Hans Van Eenennaam In Its Europe Unit

* ADURO BIOTECH APPOINTS HANS VAN EENENNAAM EXECUTIVE VICE PRESIDENT ANTIBODY RESEARCH AND SITE HEAD, ADURO BIOTECH EUROPE Source text for Eikon: Further company coverage:

Mar 05 2018

BRIEF-Aduro Biotech Q4 Loss Per Share $0.34

* ADURO BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

BRIEF-Aduro Biotech Announces Management Changes

* ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER

Jan 05 2018

BRIEF-Aduro Biotech Expands Leading Intellectual Property Position In STING Field With Newly Issued Patent

* ADURO BIOTECH EXPANDS LEADING INTELLECTUAL PROPERTY POSITION IN STING FIELD WITH NEWLY ISSUED PATENT Source text for Eikon: Further company coverage:

Dec 20 2017

BRIEF-Aduro Biotech Provides Update On CRS-207 Programs

* COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207

Dec 12 2017

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​

Nov 10 2017

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

Oct 31 2017

Earnings vs. Estimates